ASTCT Talks cover art

All Episodes

ASTCT Talks — 81 episodes

#
Title
1

Exploring CAR T Updates in Pediatric Acute Lymphoblastic Leukemia

2

Titans of Transplant Featuring Dr. Crystal Mackall

3

The Role of the Social Worker in CAR T Care

4

TIL Therapy for Solid Tumors

5

Titans of Transplant: Catherine Bollard, MBChB, MD

6

Navigating the Dynamic Landscape of Stem Cell Transplantation

7

GVHD in Pediatrics: Acute and Chronic Risk

8

Unraveling Key Hematologic Oncology Developments at ASCO 2026

9

Exploring and Managing Gastrointestinal-Related CAR T-Cell Lymphomas

10

ASTCT Talks: Gene Therapy Today and Tomorrow

11

Treatment Options for cGVHD: Adult vs. Pediatric Perspectives

12

Best Practice Considerations for Infection Prevention and Management Post-CAR T

13

LIVE From ASH: Multiple Myeloma Treatment Redefined by Bispecific Antibodies and T-Cell Therapies

14

What Clinicians Need to Know About Chronic GVHD and Immunity

15

Pulmonary Manifestations of Chronic GVHD

16

Tackling Cognitive Challenges in Survivorship Care

17

Titans of Transplant: Innovations in CAR T Cell Therapy

18

Pharmacist Takeover: BCMA Bispecifics and CAR T-Cell Therapy

19

Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors

20

Cord Blood Transplantation: Past, Present and Future Innovations

21

Managing Mental Health in Chronic GVHD

22

Physician-Patient Communication in the Post-Transplant Setting

23

Delayed Neurotoxicity With Car-T Therapy in Myeloma: What Clinicians Need To Know

24

Titans of Transplant: Dr. Daniel Weisdorf

25

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

26

Homegrown CAR-T: Expanding Access Through Academic Innovation

27

Rethinking Tacrolimus Targets in the PTCy Era

28

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

29

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

30

Understanding Cutaneous GVHD: Clinical Insights and Care Strategies

31

The Role of Lifestyle Medicine in Chronic GVHD with Dr. Steven Pavletic

32

Optimizing Graft Selection: A New Era in Transplantation with Dr. Lori Muffly

33

Oral Chronic Graft-Versus-Host Disease and Oral Health After Allogeneic Hematopoietic Cell Transplantation — What the Care Team Needs To Know

34

Titans of Transplant: Dr. Renier Brentjens

35

Understanding Ocular Graft-versus-Host Disease to Facilitate an Integrated Multidisciplinary Approach

36

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

37

Outpatient CAR T: Navigating Logistics and Patient Care

38

Bridging the Gap: Addressing Disparities in GVHD Care

39

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

40

Exploring Insights From CAR-TITUDE 4 and KarMMa-3 Trials with Dr. Jens Hillengass

41

A New Era in GVHD Prophylaxis: A Conversation With Dr. Samer Al-Homsi

42

Beyond Remission: Navigating the Late Effects of Pediatric CAR T-Cell Therapy

43

A Conversation with Mike Niles: Author of ‘Hard Graft: Our Fight Against Killer Blood’

44

Titans of Transplant: Dr. Stephanie Lee

45

Exploring the BMT CTN 1703 Study

46

Navigating CAR-T Survivorship

47

Beyond BCMA: Exploring Talquetamab in Myeloma Therapy

48

Behind the Scenes of CAR-T Therapy at University of California, Davis

49

Revitalizar, Prosperar y Sobrevivir: El Poder del Movimiento en la Recuperación de los Trasplantes

50

Revitalize, Thrive, and Survive: The Power of Movement in Transplant Recovery

51

A PTCy of Relief: GVHD Prophylaxis in Matched Unrelated Donors

52

Navigating Intersectionality in GVHD and Transplant Medicine

53

Advancing ALL Treatment and Insights on MRD Monitoring

54

Monitoring After CAR-T Therapy for Multiple Myeloma: The APP Perspective

55

Titans of Transplant: Dr. Rick Jones

56

Breaking Barriers and Dispelling Misconceptions in Transplantation

57

How to Handle CAR-T Waitlists in Multiple Myeloma

58

Treating Cytopenias After CAR T-cell Therapy

59

Bispecific Antibodies in Myeloma: The Who, What, When, and Where

60

Virus-Specific T-Cells (VST): Where We Are and How We Got Here

61

Titans of Transplant: Dr. Micah Skeens

62

MRD in Relation to Transplantation and Cell Therapy

63

The Winter "Tridemic" in Cellular Therapy

64

Titans of Transplant: Susan Slater, MN, FNP-BC

65

Monkeypox in HCT and CAR T

66

Titans of Transplant: Dr. John F. DiPersio

67

Celebrating Advocacy Efforts, Overcoming Barriers and Addressing Inequity in Cellular Transplantation

68

Titans of Transplant: Dr. Rainer Storb

69

Titans of Transplant: Dr. Adriana Seber

70

Finding Affordable and Accessible Hematopoietic Cell Transplants

71

Titans of Transplant: Dr. Krishna Komanduri

72

Managing COVID-19 in Transplant Patients

73

Titans of Transplant: Dr. Gregorio Jaimovich

74

Titans of Transplant: Dr. Mary Horowitz

75

A Deep Dive On Early Time-to-Toci

76

Advancements in Immunotherapies with Dr. DiPersio

77

Outpatient Haploidentical Stem Cell Transplantation

78

A Deep Dive on Chronic GVHD

79

The Role of MRD in Multiple Myeloma

80

MRD Negativity and Lenalidomide Maintenance Therapy: The Possible Next Chapter in Multiple Myeloma Care

81

Dr. Lia Gore Discusses Bispecific T-Cell Engagers in Pediatric ALL Research